首页> 外文期刊>British Journal of Clinical Pharmacology >Pharmacokinetics of oral betaine in healthy subjects and patients with homocystinuria.
【24h】

Pharmacokinetics of oral betaine in healthy subjects and patients with homocystinuria.

机译:口服甜菜碱在健康受试者和高半胱氨酸尿症患者中的药代动力学。

获取原文
获取原文并翻译 | 示例
       

摘要

AIMS: Large oral doses of betaine have proved effective in lowering plasma homocysteine in severe hyperhomocysteinaemia. The pharmacokinetic characteristics and metabolism of betaine in humans have not been assessed and drug monitoring for betaine therapy is not available. We studied the pharmacokinetics of betaine and its metabolite dimethylglycine (DMG) in healthy subjects and in three patients with homocystinuria. METHODS: Twelve male volunteers underwent an open-label study. After one single administration of 50 mg betaine kg-1 body weight and during continuous intake of twice daily 50 mg kg-1 body weight, serial blood samples and 24 h urines were collected to determine betaine and DMG plasma concentrations and urinary excretion, respectively. Patients were evaluated after one single dose of betaine. RESULTS: We found rapid absorption (t(1/2),abs 00.28 h, s.d. 0.17) and distribution (t(1/2),lambda1 00.59 h, s.d. 0.22) of betaine. A Cmax of 0.94 mmol l-1 (s.d. 0.19) was reached after tmax 00.90 h (s.d. 0.33). The elimination half life t(1/2),z was 14.38 h (s.d. 7.17). After repeated dosage, t(1/2),lambda1 (01.77 h, s.d. 0.75) and t(1/2),z (41.17 h, s.d. 13.50) increased significantly (95% CI 0.73, 01.64 h and 19.90, 33.70 h, respectively), whereas absorption remained unchanged. DMG concentrations increased significantly after betaine administration and accumulation occurred to the same extent as with betaine. Renal clearance was low and urinary excretion of betaine was equivalent to 4% of the ingested dose. Distribution and elimination kinetics in homocystinuric patients appeared to be accelerated. CONCLUSIONS: Betaine plasma concentrations change rapidly after ingestion. Elimination half-life increased during continuous dosing over 5 days. Betaine is mainly eliminated by metabolism. More pharmacokinetic and pharmacodynamic studies in hyperhomocysteinaemic patients are needed to refine the current treatment with betaine.
机译:目的:大剂量甜菜碱经证实可有效降低严重高同型半胱氨酸血症的血浆同型半胱氨酸。甜菜碱在人体内的药代动力学特征和代谢尚未评估,尚无法进行甜菜碱治疗的药物监测。我们研究了甜菜碱及其代谢物二甲基甘氨酸(DMG)在健康受试者和三名高半胱氨酸尿症患者中的药代动力学。方法:十二名男性志愿者接受了开放标签研究。在单次施用50 mg甜菜碱kg-1体重和连续两次每天两次摄入50 mg kg-1体重后,分别采集了连续血样和24 h尿液,分别测定了甜菜碱和DMG血浆浓度和尿液排泄量。单次服用甜菜碱后对患者进行评估。结果:我们发现甜菜碱吸收迅速(t(1/2),abs 00.28 h,s.d. 0.17)和分布(t(1/2),lambda1 00.59 h,s.d.0.22)。在t max 00.90小时(s.d.0.33)之后达到0.94mmol l-1(s.d.0.19)的Cmax。消除半衰期t(1/2),z为14.38 h(标准偏差7.17)。重复给药后,t(1/2),lambda1(01.77 h,sd 0.75)和t(1/2),z(41.17 h,sd 13.50)显着增加(95%CI 0.73,01.64 h和19.90,33.70 h ),而吸收率保持不变。甜菜碱给药后,DMG浓度显着增加,并且积累程度与甜菜碱相同。肾脏清除率低,甜菜碱的尿排泄量相当于摄入剂量的4%。高胱氨酸尿症患者的分布和消除动力学似乎加快了。结论:摄入后甜菜碱的血浆浓度迅速变化。在5天连续给药期间,消除半衰期增加。甜菜碱主要通过代谢消除。需要对高同型半胱氨酸血症患者进行更多的药代动力学和药效学研究,以完善目前甜菜碱的治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号